Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer

NCT04345783 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Camrelizumab for injection, apatinib mesylate and tegio

Sponsor

Beijing Friendship Hospital